ROPCA ApS

Odense, Denmark All Denmark companies → — Founded 2019

Imaging AI Specialist Medical Device / Hardware Specialty-Focused AI

Generating Revenue / Seed — $746K

Claim this company

About ROPCA ApS

ROPCA ApS is a Danish medtech company specializing in AI-powered robotics for musculoskeletal (MSK) ultrasound diagnostics, particularly for arthritic conditions. The company’s flagship products, ARTHUR and DIANA, aim to address the growing demand for diagnostics, limited specialist capacity, and the need for consistent diagnostic data in rheumatology. ARTHUR is an AI-powered, autonomous ultrasound robot designed to perform standardized scans of finger, hand, and wrist joints, capturing precise and consistent images regardless of operator skill. DIANA, the accompanying AI software, analyzes these images and generates automated, structured reports, providing clinicians with reliable insights for diagnosis and treatment planning.

ROPCA’s solutions are designed to support, not replace, healthcare professionals by automating repetitive and time-consuming tasks, thereby freeing up specialists to focus on patient care. Their systems are CE-marked and have been installed in clinics in Denmark since 2023 and Germany since 2024, with interest from other institutions in Europe and the U.S. ROPCA recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for ARTHUR and DIANA, marking a significant step for their expansion into the U.S. healthcare market. The company emphasizes that its technology is rooted in scientific evidence and refined through real-world clinical experience, aiming to raise ultrasound to the standard of care in arthritis diagnosis and treatment globally.

Focus Areas

musculoskeletal ultrasound rheumatoid arthritis diagnosis AI-powered medical robotics automated medical imaging clinical automation

Business Intelligence

Key Investors	unknown
Partnerships	KUKA, GE HealthCare, University of Southern Denmark (SDU), Odense University Hospital (OUH), Institute of Medical Technology, Enabled Robotics ApS, IHI AutoPiX project, Medical University of Vienna, European Federation of Pharmaceutical Industries (EFPIA)
Acquisitions	unknown
Technology	cloud-native, edge computing, AI operating system, robotic platform (KUKA LBR Med)
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Musculoskeletal Ultrasound & Rheumatoid Arthritis Diagnosis

ROPCA specializes in automating musculoskeletal (MSK) ultrasound for the diagnosis and monitoring of rheumatoid arthritis (RA) and other arthritic conditions. Their flagship product, ARTHUR, is an AI-powered, autonomous ultrasound robot that performs standardized scans of finger, hand, and wrist joints. This system aims to provide consistent, high-quality images, reducing operator variability and supporting early detection and continuous monitoring of RA. DIANA, their AI software, analyzes these ultrasound images and generates structured reports, aligning with EULAR-OMERACT standards.

AI-Powered Medical Robotics & Automated Medical Imaging

ROPCA's core innovation lies in its AI-powered medical robotics, specifically ARTHUR, the world's first autonomous ultrasound robot for arthritis diagnosis. ARTHUR automates the repetitive task of ultrasound joint scanning, capturing precise and standardized images independently of operator skill. DIANA, the AI behind ARTHUR's scans, provides automated image analysis and instantaneous, structured reporting, transforming ultrasound data into clear, reliable insights.

Clinical Automation & Efficiency

ROPCA's solutions are designed to automate routine scanning tasks, freeing clinicians to focus on patient care and interpretation. This automation maximizes patient throughput, reduces waiting times for specialist assessments, and addresses the challenge of limited rheumatological expertise. The ARTHUR and DIANA systems create an end-to-end workflow that combines consistent image acquisition with AI-assisted analysis and reporting, while keeping clinical decisions in the hands of healthcare professionals.

Physician Tip

For physicians, ROPCA's ARTHUR and DIANA systems offer a significant advantage by providing consistent, objective, and reproducible ultrasound assessments for rheumatoid arthritis. This can lead to earlier diagnosis and treatment, which is crucial for better patient outcomes. The automation of routine scans allows specialists to dedicate more time to complex cases and patient interaction. The structured reports generated by DIANA, aligned with EULAR-OMERACT standards, can streamline decision-making and ensure standardized monitoring of disease activity. Furthermore, the system can help address the growing demand for rheumatological expertise and reduce patient waiting times.

ROPCA's ARTHUR system is designed as a 'plug-and-play' solution, making it easy to integrate with standard ultrasound machines. The company collaborates with leading hospitals, research institutions, and industry partners to ensure their solutions are grounded in clinical reality and fit seamlessly into everyday clinical practice. They have also partnered with KUKA, utilizing their LBR Med cobot for ARTHUR, which is already conform to medical standards, accelerating market entry.

At a glance

Founded 2019

HQ Odense, Denmark · Denmark

Team size 21 total employees

CEO Johannes Schaeferhoff

Funding Generating Revenue / Seed — $746K

FDA clearances 2 (estimated)

Products by ROPCA ApS

No products listed for this company yet. Know of one? Suggest it →

What the Web Says

ROPCA ApS is a Danish medical technology company that has developed ARTHUR, the world's first AI-powered, fully autonomous ultrasound robot for diagnosing and treating arthritis. The company was founded in 2019 as a spin-off from the University of Southern Denmark. ARTHUR aims to address rising patient demand, limited clinical resources, and the need for consistent imaging by automating repetitive ultrasound joint scanning tasks. The system has been clinically proven for reliability and consistency, with studies demonstrating benefits for both patients and healthcare teams. ROPCA ApS products are not currently for sale in the United States.

Overall: Positive

Strengths

ARTHUR performs structured, consistent, and precise examinations thanks to AI.
It is significantly faster than manual examinations, potentially three times faster.
Over 95% of patients in validation studies were satisfied or very satisfied with the experience.
ARTHUR allows specialists to focus more on treatment by handling routine scans.
The system provides consistent and reproducible scans, independent of the operator's skill.
It helps clinics manage more patients without overworking staff.

Limitations

No specific cons were found in the provided search results regarding ROPCA ApS products or as an employer.
The products are not for sale in the United States.

Based on reviews from: ROPCA ApS (References), Will ARTHUR, The Rheumatoid Arthritis Ultrasound Robot be a Game Changer for Diagnosis?, ARTHUR - ROPCA ApS, Will arthritis robot, ARTHUR (ARTHritis Ultrasound Robot), be a game changer for diagnosis? It can autonomously perform ultrasound scans and AI analysis of the knuckles of a person's hand and d - Facebook, The world's first robot for rheumatoid arthritis diagnosis - YouTube

Last updated: 2026-09-23

Videos

News, demos, and interviews about ROPCA ApS.

Loading videos...

Videos load interactively. If none appear, search YouTube for ROPCA ApS →

View all on YouTube

Press & Coverage

Diagnostic Imaging Europe

FDA Clears ROPCA's Automated Ultrasound Robot and AI Software

Danish medtech company ROPCA has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ARTHUR and DIANA technologies, which automate elements of musculoskeletal ultrasound acquisition, analysis, and reporting. This clearance allows ROPCA to make these technologies available to healthcare providers across the United States.

2026-09

ITN Online

Danish Firm Receives FDA Clearance for Ultrasound Robot, AI Software

ROPCA, a Danish medtech company, has secured U.S. FDA 510(k) clearance for its AI-powered autonomous ultrasound robot, Arthur, and its AI software, Diana, marking a significant step for its expansion into the U.S. healthcare market. Arthur performs standardized musculoskeletal ultrasound scans, while Diana analyzes images and supports automated report generation.

2026-08

ROPCA ApS

ROPCA Receives FDA 510(k) Clearance for ARTHUR and DIANA

ROPCA, a Danish medtech company, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ARTHUR and DIANA robotic and AI-powered solutions for musculoskeletal ultrasound. This clearance is a major milestone for the company's expansion into the U.S. healthcare market.

2026-08

ROPCA ApS

ROPCA wins the UN Robots for Good award

ROPCA won the United Nations Robots for Good competition, recognized for its innovative work in robotics for healthcare. This award highlights ROPCA's commitment to using technology for positive societal impact.

2023-05

Rheumatic & Musculoskeletal Diseases (PMC)

Automated ultrasound system ARTHUR V.2.0 with AI analysis DIANA V.2.0 matches expert rheumatologist in hand joint assessment of rheumatoid arthritis patients

A study published in Rheumatic & Musculoskeletal Diseases found that ROPCA's automated ultrasound system ARTHUR V.2.0 with AI analysis DIANA V.2.0 matched expert rheumatologists in assessing hand joint rheumatoid arthritis. This suggests automation could help overcome workforce limitations in rheumatology.

2025-08

Robotics.org

Will ARTHUR, The Rheumatoid Arthritis Ultrasound Robot be a Game Changer for Diagnosis?

ROPCA ApS, a spin-off from the University of Southern Denmark, has introduced ARTHUR, an arthritis-scanning robot that can autonomously perform ultrasound scans of patients' hands. This system aims to provide earlier treatment for rheumatoid arthritis, which is crucial for successful therapy.

2024-02

YouTube (KUKA)

The world's first robot for rheumatoid arthritis diagnosis

KUKA highlights its collaboration with ROPCA ApS on the ARTHUR robot, the world's first medical product for rheumatoid arthritis diagnosis based on the lightweight robot LBR Med. ARTHUR supports early diagnosis through robot-assisted ultrasound, addressing specialist shortages.

2023-11

ROPCA ApS

ROPCA's first UK installation: ARTHUR arrives in the UK

ROPCA announced the installation of ARTHUR at Royal Berkshire Hospital, marking its first installation in the UK. This expansion aims to support clinical teams by consistently handling repetitive scanning, thereby freeing up clinicians' time.

2026-08

Frequently Asked Questions

What specific musculoskeletal ultrasound applications does ROPCA ApS's technology address, particularly in the context of rheumatoid arthritis diagnosis?

ROPCA ApS focuses on automating musculoskeletal ultrasound examinations, particularly for early and accurate diagnosis of rheumatoid arthritis. Their robotic system aims to standardize image acquisition, reducing operator dependency and improving the consistency and reliability of ultrasound assessments for inflammatory joint diseases. This automation can lead to earlier detection and more effective management of RA.

How does ROPCA ApS's AI-powered medical robotics integrate with existing clinical workflows for automated medical imaging, and what are the key benefits for a healthcare administrator?

ROPCA ApS's AI-powered robotic system is designed to integrate seamlessly into existing clinical workflows by automating the ultrasound scanning process. For healthcare administrators, this means potential benefits such as increased throughput of examinations, reduced sonographer workload, standardized image quality, and improved diagnostic accuracy, ultimately leading to more efficient resource allocation and better patient outcomes.

What are the primary clinical automation concerns addressed by ROPCA ApS's products, and how do they ensure compliance with medical device regulations and data privacy (e.g., GDPR, HIPAA)?

ROPCA ApS addresses concerns about variability in ultrasound examinations and the need for highly skilled operators by automating the process. They are committed to complying with relevant medical device regulations (e.g., MDR) and data privacy standards like GDPR and HIPAA, ensuring patient data security and the safety and efficacy of their robotic systems.

Can you provide information on the pricing structure for ROPCA ApS's robotic ultrasound systems and the available support models (e.g., training, maintenance, technical assistance)?

While specific pricing details are typically discussed directly with ROPCA ApS, their models often involve a capital expenditure for the robotic system, potentially with recurring fees for software licenses, maintenance, and support. They are expected to offer comprehensive support, including initial training for clinical staff, ongoing maintenance, and technical assistance to ensure optimal system performance and user proficiency.

What is the current stage of ROPCA ApS's product development and market availability, and what partnerships has the company established to validate or distribute its technology?

ROPCA ApS has developed a prototype of their robotic ultrasound system and is actively working towards clinical validation and market entry. They have established partnerships with key opinion leaders and research institutions to validate their technology and are likely exploring distribution channels to bring their innovative solutions to a broader healthcare market.

What is the long-term vision for ROPCA ApS regarding the expansion of its AI and robotics technology beyond musculoskeletal ultrasound, and what is the company's stability and funding status?

ROPCA ApS's long-term vision likely involves expanding its AI and robotics technology to other ultrasound applications beyond musculoskeletal, aiming to further automate and standardize medical imaging across various specialties. As a startup in a high-growth sector, their stability is supported by ongoing funding rounds and strategic investments, which are crucial for continued research, development, and market penetration.

Related Companies

Suggest an Edit →